Eckert & Ziegler forms joint venture for tumor irradiation devices in China
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Joint Venture/Miscellaneous
Berlin, 1 August 2019. Eckert & Ziegler AG (ISIN DE0005659700), a global radioisotope specialist headquartered in Berlin, Germany, has formed a joint venture with Chinese TCL Healthcare Equipment (Shanghai) Co., Ltd. (TCL Healthcare) for the development, production and distribution of advanced tumor irradiation devices highly effective against gynecological and other forms of cancer. The joint venture will trade under TCL Eckert & Ziegler BEBIG Healthcare (Wuxi) Co. Ltd. and is held 49% by EZAG and 51% by TCL. TCL Healthcare belongs to Chinese electronics group TCL Corporation with more than 16 billion USD revenues.
"We look forward to advancing brachytherapy with a strong partner in China. The tumor irradiation device produced in China and for the Chinese market opens up completely new market opportunities for us. Every year, around 4 million people in China get cancer (source: WHO). With the joint venture, we have reached another important milestone in our global growth strategy", explained Dr. Harald Hasselmann, member of the Executive Board of Eckert & Ziegler AG and Managing Director of Eckert & Ziegler BEBIG GmbH.
"Medical devices from Germany have a high standing in China. The cooperation with Eckert & Ziegler BEBIG offers us a unique opportunity to contribute our experience in development, production, approval and sales and to further develop brachytherapy for the benefit of the patients. The core competencies of both partners will complement each other perfectly in the rapidly growing Chinese healthcare market", said George Chan, Managing Director of TCL Healthcare Equipment (Shanghai) Co., Ltd.
About Eckert & Ziegler
About TCL Healthcare Equipment (Shanghai) Co., Ltd. (TCL)
About HDR brachytherapy
01.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||Eckert & Ziegler Strahlen- und Medizintechnik AG|
|Phone:||+49 30 941084-138|
|Fax:||+49 30 941084-112|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||850161|
|End of News||DGAP News Service|